Innovation Pharmaceuticals Inc (IPIX)

[thefamilyman]

Touché. However, you did say “twice as many patients” not twice the “percentage” but regardless I should have audited the numbers myself.

Sunspotter said,

How do you account for the fact that brilacidin had twice as many patients experiencing at least one AE in this study than the active comparator, daptomycin?

However, your point is still problematic because Lemoncat’s arguments on this point are correct.

Lemoncat said,

It's a useless comparison. AEs don't matter because most of them are harmless or near harmless - in the context of moderate-severe COVID they don't matter. Tingling fingers and toes for a few hours is not a problem when the alternative is that the only thing that soothes the burning of your lungs is the viscous fluid that slowly accumulates and drowns you to death.